CYP4F3 Activators
CYP4F3 activators can be divided into two main groups based on their biochemical mechanisms. The first group, consisting of Arachidonic Acid, Leukotriene B4, Eicosapentaenoic acid, and Docosahexaenoic acid, are direct substrates for CYP4F3. The enzyme metabolizes these fatty acids to their respective hydroxylated products. The functional activity of CYP4F3 is enhanced by these compounds due to increased substrate availability, driving the enzymatic reaction forward. The presence of 17-octadecynoic acid, a suicide inhibitor, can further enhance this activity by selectively modifying the active site of CYP4F3 and reducing competition from alternate substrates.
The second group of CYP4F3 activators, including Nordihydroguaiaretic acid, Zileuton, Baicalein, Curcumin, Licofelone, and MK886, work indirectly by inhibiting enzymes that share substrates with CYP4F3. These inhibitors target lipoxygenases, COX-2, and 5-lipoxygenase-activating protein (FLAP), enzymes that compete with CYP4F3 for the same substrates. By inhibiting these enzymes, the availability of substrates such as arachidonic acid and Leukotriene B4 for CYP4F3 increases, which in turn enhances the functional activity of CYP4F3. NADPH is a crucial co-factor for CYP4F3, and it provides the necessary electrons for the enzymatic reaction. Therefore, increased availability of NADPH can enhance CYP4F3 functionality by ensuring sufficient electron transfer.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Arachidonic Acid (20:4, n-6) | 506-32-1 | sc-200770 sc-200770A sc-200770B | 100 mg 1 g 25 g | $92.00 $240.00 $4328.00 | 9 | |
Arachidonic Acid is a substrate for CYP4F3 which metabolizes it to hydroxyeicosatetraenoic acids (HETEs). Increased levels of Arachidonic Acid can enhance the functional activity of CYP4F3, specifically by increasing substrate availability. | ||||||
LTB4 (Leukotriene B4) | 71160-24-2 | sc-201043 | 50 µg | $374.00 | 4 | |
Leukotriene B4, another substrate for CYP4F3, is metabolized to omega-hydroxy leukotriene B4. Increased levels of Leukotriene B4 can promote CYP4F3 activity by providing more substrate for metabolism. | ||||||
Direct red 23 | 3441-14-3 | sc-214909 | 50 g | $87.00 | ||
17-octadecynoic acid, a suicide inhibitor of fatty acid metabolism, can selectively modify the active site of CYP4F3, leading to its enhanced activity by the prevention of alternate substrate competition. | ||||||
NDGA (Nordihydroguaiaretic acid) | 500-38-9 | sc-200487 sc-200487A sc-200487B | 1 g 5 g 25 g | $109.00 $384.00 $2190.00 | 3 | |
Nordihydroguaiaretic acid is a lipoxygenase inhibitor which can indirectly enhance CYP4F3 activity by increasing the availability of arachidonic acid, a shared substrate with lipoxygenase enzymes. | ||||||
Baicalein | 491-67-8 | sc-200494 sc-200494A sc-200494B sc-200494C | 10 mg 100 mg 500 mg 1 g | $32.00 $42.00 $162.00 $292.00 | 12 | |
Baicalein is a 12/15-lipoxygenase inhibitor that can increase the availability of shared substrates with CYP4F3, thus potentially enhancing its activity. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin acts as a dual 5-lipoxygenase and COX-2 inhibitor, increasing the availability of arachidonic acid, a common substrate, and thus potentially enhancing CYP4F3 activity. | ||||||
MK-886 sodium salt | 118427-55-7 | sc-200608B sc-200608 sc-200608A | 1 mg 5 mg 25 mg | $47.00 $95.00 $378.00 | 3 | |
MK886 is an inhibitor of the 5-lipoxygenase-activating protein (FLAP). By inhibiting FLAP, MK886 increases the availability of Leukotriene B4, a substrate of CYP4F3, leading to enhanced enzyme activity. | ||||||
Eicosa-5Z,8Z,11Z,14Z,17Z-pentaenoic Acid (20:5, n-3) | 10417-94-4 | sc-200766 sc-200766A | 100 mg 1 g | $104.00 $431.00 | ||
Eicosapentaenoic acid (EPA) is a fatty acid that can serve as an alternate substrate for CYP4F3, potentially enhancing its activity by increasing substrate availability. | ||||||
Docosa-4Z,7Z,10Z,13Z,16Z,19Z-hexaenoic Acid (22:6, n-3) | 6217-54-5 | sc-200768 sc-200768A sc-200768B sc-200768C sc-200768D | 100 mg 1 g 10 g 50 g 100 g | $94.00 $210.00 $1779.00 $8021.00 $16657.00 | 11 | |
Docosahexaenoic acid (DHA) is another fatty acid that can serve as an alternate substrate for CYP4F3, potentially enhancing its activity by increasing substrate availability. | ||||||
NADPH tetrasodium salt | 2646-71-1 | sc-202725 sc-202725A sc-202725B sc-202725C | 25 mg 50 mg 250 mg 1 g | $47.00 $84.00 $286.00 $754.00 | 11 | |
NADPH is an essential co-factor for CYP4F3, providing the necessary electrons for the enzymatic reaction. Increased availability of NADPH can enhance CYP4F3 functionality by ensuring sufficient electron transfer. | ||||||